<DOC>
	<DOCNO>NCT03061721</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study 104 patient diagnosis NAFLD and/or NASH . The study conduct period 22 week include Screening Phase , 16-week Treatment Phase follow randomization . Patients randomly assign ratio 1:1:1:1 receive Saroglitazar Magnesium 1mg 2 mg 4 mg match placebo daily morning breakfast 16 Weeks . The primary endpoint study percentage change baseline serum ALT level Week 16 Saroglitazar Magnesium group compare placebo group .</brief_summary>
	<brief_title>Saroglitazar Magnesium Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Males female , 18 75 year age , body mass index ( BMI ) 25 40 kg/m2 . 2 . Documented diagnosis NAFLD establish either image ( ultrasound , CT scan MRI ) liver biopsy show NASH simple steatosis , within 12 month precede Visit 1 . The diagnosis NAFLD make accord American Association Study Liver Diseases ( AASLD ) criterion ( Chalasani et al . Hepatology 2012 ; 55:20052023 ) . 3 . ALT level ≥ 1.5 × ULN Visit 1 Visit 2 &lt; 30 % variance level Visit 1 Visit 2 . 4 . Patient 's demonstration understanding study requirement treatment procedure , willingness comply protocolrequired evaluation ; provision write informed consent study specific test procedure perform . 1 . Consumption &gt; 3 unit alcohol per day ( &gt; 21 unit per week ) male &gt; 2 unit alcohol per day ( &gt; 14 unit per week ) female least 3 consecutive month 5 year precede Visit 1 ( Note : 1 unit = 12 ounce beer , 4 ounce wine 1 ounce spirits/hard liquor ) . 2 . Presence alternative cause fatty liver , include : 1 . Weight change &gt; 5 % within 3 month precede Visit 1 2 . Total parenteral nutrition , starvation proteincalorie malnutrition within 90 day precede Visit 1 . 3 . Use drug associate NAFLD 12 consecutive week 1 year Visit 1 , include amiodarone , tamoxifen , methotrexate , systemic glucocorticoid , anabolic steroid , tetracycline , estrogens dos higher used oral contraceptive , vitamin A , L asparaginase , valproate , chloroquine antiretroviral drug 3 . Use vitamin E ( &gt; 100 IU/day ) multivitamins contain vitamin E ( &gt; 100 IU/day ) 3 month precede Visit 1 . 4 . Use drug potential effect NASH ursodeoxycholic acid , Sadenosylmethionine ( SAMe ) , betaine , pentoxifylline , obeticholic acid milk thistle 3 month prior Visit 1 . 5 . Changing dos statin ( simvastatin , pitavastatin , pravastatin , atorvastatin , fluvastatin , lovastatin , rosuvastatin ) fibrates ( clofibrate , fenofibrate ) 3 month precede Visit 1 . 6 . Use thiazolidinediones ( pioglitazone , rosiglitazone ) . 7 . Use drug know CYP2C8 inhibitors/substrate 8 . History bowel surgery ( gastrointestinal ( bariatric ) surgery undergoing evaluation bariatric surgery obesity , extensive smallbowel resection orthotopic liver transplant ( OLT ) list OLT . 9 . History chronic liver disease ( chronic hepatitis C , ( HCV ) infection , irrespective mRNA HCV assay status active hepatitis B infection , ( i.e. , serum positive hepatitis B surface antigen ) autoimmune hepatitis , cholestatic metabolic liver disease ) hemochromatosis 10 . Patient known cirrhosis , either base clinical criterion liver histology . 11 . Patient INR &gt; 1.3 . 12 . Type 1 diabetes mellitus . 13 . Poorly control type 2 diabetes mellitus , i.e. , glycosylated hemoglobin ( HbA1c ) &gt; 9 % . 14 . Unstable cardiovascular disease , include : 1. unstable angina , ( i.e. , new worsen symptom coronary heart disease within 3 month precede Visit 1 ) , acute coronary syndrome within 6 month precede Visit 1 , acute myocardial infarction within 3 month precede Visit 1 heart failure New York Heart Association class ( III IV ) worsen congestive heart failure , coronary artery intervention , within 6 month precede Visit 1 2. history ( within 3 month precede Visit 1 ) current unstable cardiac dysrhythmias 3. uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 160 mmHg and/or diastolic BP &gt; 100 mmHg ) 4. stroke transient ischemic attack within 6 month precede Visit 1 . 15 . History myopathy evidence active muscle disease . 16 . History malignancy 5 year precede Visit 1 and/or active neoplasm exception resolve superficial nonmelanoma skin cancer . 17 . Any following laboratory value : 1 . Hemoglobin &lt; 9 g/dL 2 . White blood cell count &lt; 2.5 × 103/μL 3 . Neutrophil count &lt; 1.5 × 103/μL 4 . Platelets &lt; 100 × 103/μL 5 . Total Serum bilirubin &gt; 1.5 mg/dL ( except patient know Gilbert bilirubin TB 2.5 mg/dL allow ) , &lt; 1.5 mg/dL screen &gt; 30 % variance level Visit 1 Visit 2 6 . Albumin &lt; 3.2 g/dL 7 . Serum creatinine &gt; 1.5 mg/dL 8 . Serum ALT AST &gt; 250 IU/L Visit 1 Visit 2 &lt; 250 IU/L screening , &gt; 30 % variance level Visit 1 Visit 2 . 18 . Contraindications Saroglitazar Magnesium condition affect ability evaluate effect Saroglitazar Magnesium . 19 . Known allergy , sensitivity intolerance study drug , placebo formulation ingredient . 20 . Participation therapeutic clinical study within 3 month precede Visit 1 , include participation NAFLD/NASH clinical trial . 21 . History bladder disease and/or hematuria current hematuria except due urinary tract infection . 22 . Illicit substance abuse within 12 month precede Visit 1 . 23 . Pregnancyrelated exclusion , include : 1 . Pregnant/lactating female ( include positive serum pregnancy test Visit 1 ) 2 . Fertile woman men , UNLESS use effective contraceptive method , intrauterine device mechanical contraception method condom diaphragm spermicide ) throughout study . For male patient , contraception measure ( condom spermicide ) must take study , either male participant female partner . ( Note : Enrolled female otherwise must surgically sterilize least 6 month precede Visit 1 postmenopausal , define 12 month menses without alternative medical cause ) . 24 . History evidence severe illness condition would make patient , opinion investigator , unsuitable study ( poorly control psychiatric disease , HIV , coronary artery disease active gastrointestinal condition might interfere drug absorption ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NASH</keyword>
	<keyword>NAFLD</keyword>
	<keyword>Saroglitazar</keyword>
</DOC>